Regulation, Function, and Expression of Matrix Metalloproteinase-9 in Colon, Lung, and Breast Cancers In Silico and Experimental Methods From Iraqi Metastatic Patients
Abstract
Background
Various molecular cancer variables, including K-RAS, B-RAF, and HER2/neu, are essential in the growth and advancement of tumors. Matrix metalloproteinase-9 (MMP-9) is suggested as a biomarker that is excessively produced in different types of malignancies and plays a critical role in chemotherapy resistance that leads to tumor progression and metastasis.
Patients and Methods
The study used two different methods to evaluate the expression level of MMP9. First, we sought to find its expression and interaction with other proteins or genes using in slico techniques. Second, we evaluated the protein levels of MMP-9 in 80 metastatic patients with breast, colon, and lung cancer using enzyme-linked immunosorbent assay (ELISA) techniques.
Results
In silico techniques showed a high expression of MMP9 gene in all three types of cancer. Furthermore, genes and proteins that interact the most with MMP9 were discovered using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and Human Protein Atlas (HPA). It was found that the genes associated with MMP9 gene in colon, lung, and breast cancers are MMP2 and TIMP2, along with MAPK, PI3K, and NF-κB pathways as the most significant genes and pathways across all three types of cancer that could be linked to the MMP9 gene in cancer metastasis. In addition, ELISA techniques showed that MMP9 was at the highest level in metastatic colon cancer patients at 0.62 ± 0.25, followed by breast and lung metastatic patients.
Conclusion
MMP9 appears to play a crucial role in progression of particularly colon metastatic cancer and could be targeted alongside other genes as a possible therapeutic target for this type of cancer in patients with chemotherapy resistance and metastasis.
© 2025 Hamad Ali Hamad, Yamama Farouk Shakir, Omar Tareq Zaidan, Aymen Adnan Rafea, Nur Fariesha Md Hashim, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.